Antibodies against the metabotropic glutamate receptor 5 (mGluR5) were first reported by Lancaster et al. in 2011, in the context of two young patients diagnosed with Ophelia syndrome, which is characterized by Hodgkin lymphoma and limbic encephalitis with psychosis and memory symptoms [43]. This evidence concerns the gene GRM5 and Hodgkins lymphoma.